Literature DB >> 8504566

Cardiac-specific immunoenzymometric assay of troponin I in the early phase of acute myocardial infarction.

C Larue1, C Calzolari, J P Bertinchant, F Leclercq, R Grolleau, B Pau.   

Abstract

The screening by immunoenzymometric assay (IEMA) of 784 monoclonal antibody (MAb) combinations resulted in the selection of an optimal pair of MAbs for measuring human cardiac troponin I (TnI). Using a one-step IEMA described here, we were able to detect TnI within the range of 0.2-20 micrograms/L in 30 min at room temperature. No cross-reactivity was observed with the skeletal isoforms of troponin up to a concentration of 500 micrograms/L. This assay was used to measure cardiac TnI in the plasma of 43 patients with acute myocardial infarction (AMI). TnI was detected relatively early after the onset of chest pain (4.3 +/- 2.1 h, mean +/- SD); the peak occurred after 12.2 +/- 4.6 h in a population that had undergone fibrinolysis. TnI disappearance was generally observed between 5 and 9 days after the onset of chest pain. No cardiac TnI could be detected in 145 healthy donors or in a control group of 6 patients (with skeletal damage or rhabdomyolysis). This assay allows a specific diagnosis of AMI in its early acute phase, with a high diagnostic specificity and sensitivity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8504566

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  15 in total

1.  Calpain, calpastatin activities and ratios during myocardial ischemia-reperfusion.

Authors:  D Enns; M Karmazyn; J Mair; A Lercher; J Kountchev; A Belcastro
Journal:  Mol Cell Biochem       Date:  2002-12       Impact factor: 3.396

2.  Prognostic value of continuous ST-segment monitoring in patients with non-ST-segment elevation acute coronary syndromes.

Authors:  Carlos Aguiar; Jorge Ferreira; Ricardo Seabra-Gomes
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-01       Impact factor: 1.468

Review 3.  Cardiac myofibrillar proteins: biochemical markers to estimate myocardial injury.

Authors:  K H Haider; W H Stimson
Journal:  Mol Cell Biochem       Date:  1999-04       Impact factor: 3.396

Review 4.  Biochemical markers of myocardial necrosis in acute myocardial infarction and thrombolysis.

Authors:  S Hornykewycz; H Gabriel; K Huber
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

5.  Analytical validation of cardiac troponin I assays in horses.

Authors:  Tanya M Rossi; Peter A Kavsak; M Grant Maxie; David L Pearl; W Glen Pyle; Peter W Physick-Sheard
Journal:  J Vet Diagn Invest       Date:  2017-12-10       Impact factor: 1.279

6.  Protective effect of sesamol against myocardial infarction caused by isoproterenol in Wistar rats.

Authors:  Lakshmanan Vennila; Kodukkur Viswanathan Pugalendi
Journal:  Redox Rep       Date:  2010       Impact factor: 4.412

7.  Role of alpha-actin in muscle damage of injured athletes in comparison with traditional markers.

Authors:  Antonio Martínez Amat; Juan Antonio Marchal Corrales; Fernando Rodríguez Serrano; Houria Boulaiz; Jose Carlos Prados Salazar; Fidel Hita Contreras; Octavio Caba Perez; Esmeralda Carrillo Delgado; Ignacio Martín; Antonia Aranega Jimenez
Journal:  Br J Sports Med       Date:  2007-02-22       Impact factor: 13.800

8.  Chest pain with nondiagnostic electrocardiogram in the emergency department: a randomized controlled trial of two cardiac marker regimens.

Authors:  E Dagnone; C Collier; W Pickett; N Ali; M Miller; D Tod; R Morton
Journal:  CMAJ       Date:  2000-05-30       Impact factor: 8.262

9.  Postmortem cardiac troponin-I levels predict intramyocardial damage at autopsy.

Authors:  Sara O Vargas; Christine Grudzien; Milenko J Tanasijevic
Journal:  J Thromb Thrombolysis       Date:  2007-12-07       Impact factor: 2.300

10.  Role of cardiac troponin I in the evaluation of myocardial injury.

Authors:  N V Bhagavan; A P Goldstein; S A Honda; J Uyehara; J Blaisdell; C Sugiyama; L Murakami; L Kang; G Fujitani
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.